An observational study in Exudative Age-related Macular Degeneration, sponsored by Medical University of Lublin. Completed. Per ClinicalTrials.gov, last updated 2018-11-16.
Sponsored by Medical University of Lublin · Observational
The aim of this study is to evaluate the effect of repeated intravitreal bevacizumab injections on blood-aqueous barrier permeability in eyes with neovascular age-related macular degeneration (AMD).
1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.
This study's enrollment of 48 is below the median of 106 across 421 observational studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →Medical University of Lublin is the lead sponsor of 60 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
primary care clinic
Exclusion Criteria:
Drug: Bevacizumab Injection
Anterior chamber (AC) inflammation evaluated with laser flare photometry.
All patients were examined before and 1 day and 1 month after each intravitreal bevacizumab injection. Subjects were followed for a period of 4 months in both the study and control groups. The final flare photometry value was automatically calculated by averaging 5 individual measurements. A total of 7 measurements were obtained, but the highest and lowest measurement values were excluded by the flare meter. All statistical analyses were performed using STATISTICA 12 statistical software.
Time frame: 4 months
No study locations are listed for this record.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Lublin